226 related articles for article (PubMed ID: 30190967)
1. Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer.
Ciombor KK; Goldberg RM
Hepat Oncol; 2014 Jun; 1(3):331-345. PubMed ID: 30190967
[TBL] [Abstract][Full Text] [Related]
2. Targeting metastatic colorectal cancer - present and emerging treatment options.
Ciombor KK; Berlin J
Pharmgenomics Pers Med; 2014; 7():137-44. PubMed ID: 25045279
[TBL] [Abstract][Full Text] [Related]
3. Sequencing of treatment in metastatic colorectal cancer: where to fit the target.
Temraz S; Mukherji D; Shamseddine A
World J Gastroenterol; 2014 Feb; 20(8):1993-2004. PubMed ID: 24616571
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review.
Xie X; Zhang J; Hu H; Cai Y; Wu Z; Ling J; Li W; Deng Y
Adv Ther; 2020 Oct; 37(10):4233-4248. PubMed ID: 32770529
[TBL] [Abstract][Full Text] [Related]
5. Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers.
Kasi PM; Hubbard JM; Grothey A
Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):273-6. PubMed ID: 25579664
[TBL] [Abstract][Full Text] [Related]
6. Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer.
Bekaii-Saab T; Wu C
Crit Rev Oncol Hematol; 2014 Jul; 91(1):9-34. PubMed ID: 24534706
[TBL] [Abstract][Full Text] [Related]
7. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
[TBL] [Abstract][Full Text] [Related]
9. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.
Ciombor KK; Bekaii-Saab T
Oncologist; 2018 Jan; 23(1):25-34. PubMed ID: 29021377
[TBL] [Abstract][Full Text] [Related]
10. Current and advancing treatments for metastatic colorectal cancer.
Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
[TBL] [Abstract][Full Text] [Related]
11. Molecularly targeted drugs for metastatic colorectal cancer.
Cheng YD; Yang H; Chen GQ; Zhang ZC
Drug Des Devel Ther; 2013; 7():1315-22. PubMed ID: 24204124
[TBL] [Abstract][Full Text] [Related]
12. Emerging treatments in recurrent and metastatic colorectal cancer.
Ciombor KK; Bekaii-Saab T
J Natl Compr Canc Netw; 2013 Sep; 11 Suppl 4(Suppl 4):S18-27. PubMed ID: 24158967
[TBL] [Abstract][Full Text] [Related]
13. Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor.
Weinberg BA; Hartley ML; Salem ME
Oncology (Williston Park); 2017 Jul; 31(7):539-48. PubMed ID: 28712098
[TBL] [Abstract][Full Text] [Related]
14. New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer.
Sánchez-Gundín J; Fernández-Carballido AM; Martínez-Valdivieso L; Barreda-Hernández D; Torres-Suárez AI
Int J Med Sci; 2018; 15(7):659-665. PubMed ID: 29910669
[TBL] [Abstract][Full Text] [Related]
15. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
Al-Marrawi MY; Saroya BS; Brennan MC; Yang Z; Dykes TM; El-Deiry WS
Cancer Biol Ther; 2013 Aug; 14(8):703-10. PubMed ID: 23792568
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
Kirstein MM; Lange A; Prenzler A; Manns MP; Kubicka S; Vogel A
Oncologist; 2014 Nov; 19(11):1156-68. PubMed ID: 25326159
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling in the treatment of colorectal cancer: focus on regorafenib.
Yan Y; Grothey A
Onco Targets Ther; 2015; 8():2949-57. PubMed ID: 26508880
[TBL] [Abstract][Full Text] [Related]
18. Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review.
Koilakou S; Petrou P
Mol Diagn Ther; 2021 Nov; 25(6):715-734. PubMed ID: 34816395
[TBL] [Abstract][Full Text] [Related]
19. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C
Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946
[TBL] [Abstract][Full Text] [Related]
20. Role of Biologics in First-Line Treatment of Colorectal Cancer.
Mahipal A; Grothey A
J Oncol Pract; 2016 Dec; 12(12):1219-1228. PubMed ID: 27943689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
